会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 생체적합성이 우수한 코어/쉘 나노복합체, 이의 제조방법 및 이를 이용한 MRI 조영제, 암 치료용 NCT 시약
    • 具有生物相容性的核/壳纳米微粒,其制备方法和使用该方法的MRI对照介质,使用NCT的NCT用于治疗癌症
    • KR1020120072404A
    • 2012-07-04
    • KR1020100134130
    • 2010-12-24
    • 경북대학교 산학협력단
    • 정인우조희경
    • A61K9/127A61K9/28A61K49/06A61P35/00
    • A61K9/0092A61K41/009A61K49/085A61K49/101A61K49/183A61K49/1854B82Y5/00G01N2800/102
    • PURPOSE: A core/shell nanocomposite with excellent biocompatibility and a method for preparing the same are provided to enhance long-term blood circulation. CONSTITUTION: A core/shell nanocomposite contains a core formed of gadolinium oxide(Gd_2O_3) nanoparticles, a silica shell(SiO_2) covering the core outer circumference, and a poly(2-methacryloyloxyethyl phosphorylcholine) coating layer on the surface of the silica shell. The average particle of the nanoparticle is 20-100 nm. The average of the silica shell is 10-50 nm. A method for preparing the nanocomposite comprises: a step of mixing a mixture solution of gadolinium oxide nanoparticle and dialkylene glycol, APTES(3-aminopropyltriethoxysilane) of chemical formula 1, and TEOS(tetraethoxy silicate); a step of adding TEA(triethanolamine) and performing polyol reaction and sol-gel reaction to prepare a Gd_2O_3/SiO_2-X complex-containing solution; a step of mixing the Gd_2O_3/SiO_2-X complex-containing solution and C1-C3 alcohol; and a step of adding ligand and 2-methacryloyloxyethyl phosphocholine monomers.
    • 目的:提供具有优异生物相容性的核/壳纳米复合材料及其制备方法,以增强长期血液循环。 构成:核/壳纳米复合材料包含由氧化钆(Gd_2O_3)纳米颗粒,覆盖芯外周的二氧化硅壳(SiO_2)和二氧化硅壳表面上的聚(2-甲基丙烯酰氧乙基磷酰胆碱)涂层形成的核心。 纳米颗粒的平均颗粒为20-100nm。 二氧化硅壳的平均值为10-50nm。 制备纳米复合材料的方法包括:将化学式1的APTES(3-氨基丙基三乙氧基硅烷)和TEOS(四乙氧基硅酸酯)的混合溶液钆氧化物纳米颗粒和二亚烷基二醇的混合物的步骤。 加入TEA(三乙醇胺)并进行多元醇反应和溶胶 - 凝胶反应以制备含有Gd_2O_3 / SiO_2-X络合物的溶液的步骤; 混合含有Gd_2O_3 / SiO_2-X络合物的溶液和C1-C3醇的步骤; 以及添加配体和2-甲基丙烯酰氧基乙基磷酸胆碱单体的步骤。
    • 5. 发明公开
    • 암진단용 MR 조영제와 그 제조방법
    • 对比介质及其制备方法
    • KR1020090096816A
    • 2009-09-15
    • KR1020080021866
    • 2008-03-10
    • 경북대학교 산학협력단
    • 장용민김태정박지애
    • A61K51/08A61K51/02A61K51/00
    • A61K49/14A61K49/085
    • An MR (magnetic resonance) contrast medium for diagnosing cancer, which contains a peptide and Gd precursor is provided to improve selective specificity to a cancer cell and reduce cytotoxicity. An MR (magnetic resonance) contrast medium for diagnosing cancer comprises a peptide containing a ligand and RGD (Arg-Gly-Asp) sequence and Gd precursor. A method for manufacturing MR contrast medium comprises: a step of esterifying the peptide containing the ligand and RGD sequence; and a step of binding Gd (gadolinium) precursor on the esterified compound. The ligand is DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DPTA (Diethylenetriamine pentaacetic acid) or DO3A (1,4,7,10-tetraazacyclododecan).
    • 提供用于诊断癌症的MR(磁共振)造影剂,其包含肽和Gd前体,以改善对癌细胞的选择性特异性并降低细胞毒性。 用于诊断癌症的MR(磁共振)造影剂包含含有配体和RGD(Arg-Gly-Asp)序列和Gd前体的肽。 制造MR造影剂的方法包括:使含有配体和RGD序列的肽酯化的步骤; 以及在所述酯化化合物上结合Gd(钆)前体的步骤。 配体是DOTA(1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸),DPTA(二亚乙基三胺五乙酸)或DO 3 A(1,4,7,10-四氮杂环十二烷)。
    • 9. 发明公开
    • MRI 유도 광역학 암 치료
    • MRI指导癌症的光化疗法
    • KR1020070086803A
    • 2007-08-27
    • KR1020077014910
    • 2005-12-02
    • 유니버시티 오브 유타 리써치 파운데이션
    • 루쩡-롱비아디아아나가커티엔이
    • A61K49/06A61K39/385A61P35/00
    • A61K49/085A61K41/0071A61K47/645A61K49/146
    • Disclosed is a method of therapy used in combination with a diagnostic tool for enhanced photodynamic therapy using MRI, called (magnetic resonance imaging)-guided photodynamic therapy. The methods of the present invention includes administration of MRI contrast agent labeled polymer photosensitizer conjugates, detection and localization of tumor or cancer tissues with contrast-enhanced MRI and specific illumination and treatment of localized target tissues, such as tumors or cancer cells, using laser energy. The delivered laser energy activates the photosentizer accumulated in the target tissue, resulting in treatment. Also disclosed are novel conjugate compounds, such as PLGA-Mce6-DOTA-Gd complexes, having multi-functionality in that the complex may include an MRI contrasting agent linked to a photosensitizing agent.
    • 公开了一种治疗方法,与用于使用称为(磁共振成像) - 光导光疗法的MRI的增强光动力疗法的诊断工具结合使用。 本发明的方法包括施用MRI造影剂标记的聚合物光敏剂缀合物,使用对比度增强的MRI和特定照明的肿瘤或癌组织的检测和定位以及使用激光能量的局部靶组织如肿瘤或癌细胞的治疗 。 递送的激光能量激活积聚在靶组织中的光敏剂,从而进行治疗。 还公开了具有多功能性的新型缀合物化合物,例如PLGA-Mce6-DOTA-Gd复合物,因为该复合物可包括与光敏剂连接的MRI造影剂。